Xiaoping Zhao, Fajun Yang
Department of Medicine and Molecular & Developmental Biology, Diabetes Research Center, Albert Einstein College of Medicine, 1301 Morris Park Avenue, Bronx, NY 10461, USA.
Sheng Wu Wu Li Hsueh Bao. 2012;28(4):287-294. doi: 10.3724/SP.J.1260.2012.20034.
The sterol regulatory element-binding proteins (SREBPs) play an important role in regulating lipid homeostasis. Translated as inactive precursors that are localized in the endoplasmic reticulum (ER) membrane, SREBPs are activated through a proteolytic process in response to intracellular demands for lipids. The cleaved amino-terminal fragments of SREBPs then translocate into the nucleus as homodimers and stimulate the transcription of target genes by binding to the sterol response elements (SREs) in their promoters. Numerous studies using cell culture or genetically modified mouse models have demonstrated that the major target genes of SREBPs include rate-limiting enzymes in the pathways of fatty acid and cholesterol biosynthesis as well as the low-density lipoprotein (LDL) receptor. The proteolytic maturation of SREBPs has been well studied in the past. However, recent studies have also improved our understanding on the regulation of nuclear SREBPs. In the nucleus, SREBPs interact with specific transcriptional cofactors, such as CBP/p300 and the Mediator complex, resulting in stimulation or inhibition of their transcriptional activities. In addition, nuclear SREBP protein stability is dynamically regulated by phosphorylation and acetylation. Such protein-protein interactions and post-translational modifications elegantly link the extracellular signals, such as insulin, or intracellular signals, such as oxidative stress, to lipid biosynthesis by modulating the transcriptional activity of SREBPs. Under normal physiological states, lipid homeostasis is strictly maintained. However, the SREBP pathways are often dysregulated in pathophysiological conditions, such as obesity, type 2 diabetes, and fatty liver diseases. Thus, the novel regulatory mechanisms of SREBPs may provide new opportunities for fighting these metabolic diseases.
固醇调节元件结合蛋白(SREBPs)在调节脂质稳态中发挥着重要作用。SREBPs作为无活性前体被翻译并定位于内质网(ER)膜,通过蛋白水解过程被激活以响应细胞内对脂质的需求。SREBPs被切割后的氨基末端片段随后以同二聚体形式转运到细胞核中,并通过与启动子中的固醇反应元件(SREs)结合来刺激靶基因的转录。许多使用细胞培养或基因改造小鼠模型的研究表明,SREBPs的主要靶基因包括脂肪酸和胆固醇生物合成途径中的限速酶以及低密度脂蛋白(LDL)受体。过去对SREBPs的蛋白水解成熟过程已有充分研究。然而,最近的研究也增进了我们对核内SREBPs调控的理解。在细胞核中,SREBPs与特定的转录辅因子相互作用,如CBP/p300和中介体复合物,从而刺激或抑制它们的转录活性。此外,核内SREBP蛋白的稳定性受到磷酸化和乙酰化的动态调控。这种蛋白质-蛋白质相互作用和翻译后修饰通过调节SREBPs的转录活性,巧妙地将细胞外信号(如胰岛素)或细胞内信号(如氧化应激)与脂质生物合成联系起来。在正常生理状态下,脂质稳态得到严格维持。然而,在病理生理条件下,如肥胖、2型糖尿病和脂肪肝疾病中,SREBP途径常常失调。因此,SREBPs的新型调控机制可能为对抗这些代谢性疾病提供新的机会。